China Biotech Services (08037) and Stella Pharma signed a master cooperation agreement to jointly advance the development and commercialization of Steboronine® in China

Zhitongcaijing · 1d ago

Zhitong Finance App News, China Biotech Service (08037) announced that continued cooperation with Stella Pharma has entered a new phase. On August 11, 2026, the company, Pengbo (Hainan) Boron Neutron Medical Technology Co., Ltd. (Pengbo (Hainan)) and Stella Pharma signed a legally binding master cooperation agreement on the development and commercialization of Steboronine® in China.

The cooperation under the main cooperation agreement is divided into two stages, the development stage and the commercialization stage. After Stella Pharma obtains approval from the State Drug Administration, Pengbo (Hainan) will automatically become the exclusive domestic agent of Steboronine® in China. After Stella Pharma obtains approval from the National Drug Administration, the company (or its designated controlled entity) will automatically become the sole general import agent/distributor of Steboronine® in China. The main cooperation agreement is valid for 10 years from the date of signing until Stella Pharma obtains approval from the China Drug Administration. However, if the exclusive distribution period is extended, the term of the main cooperation agreement will automatically be extended accordingly.

This cooperation forms a synergy with the Group's flagship project at Pengbo Hainan Boron Neutron Hospital, marking the Group's important strategic initiative to introduce advanced boron neutron therapy technology into the Chinese market to further consolidate and develop its business in China, accelerate the Group's layout in the upstream boron neutron therapy industry, and strengthen its future competitiveness.